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Abstract
Identification of neutralizing antibodies with specificity away from the traditional mutation prone
antigenic regions, against the conserved regions of hemagglutinin from H5N1 influenza virus has the
potential to provide a therapeutic option which can be developed ahead of time in preparation for
a possible pandemic due to H5N1 viruses. In this study, we used a combination of panning strategies
against the hemagglutinin (HA) of several antigenic distinct H5N1 isolates to bias selection of Fab-
phage from a naïve human library away from the antigenic regions of HA, toward the more
conserved portions of the protein. All of the identified Fab clones which showed binding to multiple
antigenically distinct HA were converted to fully human IgG, and tested for their ability to
neutralize the uptake of H5N1-virus like particles (VLP) into MDCK cells. Five of the antibodies
which showed binding to the relatively conserved HA2 subunit of HA, exhibited neutralization of
H5N1-VLP uptake in a dose dependant manner. The inhibitory effects of these five antibodies were
similar to those observed with a previously described neutralizing antibody specific for the 140s
antigenic loop present within HA1 and highlight the exciting possibility that these antibodies may
be efficacious against multiple H5N1 strains.
Background
Human disease due to direct transmission of highly path-
ogenic avian influenza A virus (HPAI) of the subtype
H5N1 from poultry was first reported in 1997 and
resulted in the death of 6 of the 18 infected individuals [1-
3]. Re-emergence of HPAI-H5N1 viruses occurred in 2003
and to date has continued to be a cause of disease in both
humans and poultry [4]. Currently H5N1 strains do not
transmit efficiently between people, a trait that has prob-
ably limited the spread to the human population, and
most human cases remain a result of a direct bird-to-
human transmission [5] As at mid-January 2008, there
have been 349 reported cases of human H5N1 infection
with a high mortality rate resulting in the death of 216
individuals. Since 2003, increased geographical distribu-
tion (H5N1 has been reported in a variety of birds from
over 50 countries) coupled with continued evolution of
H5N1 viruses and an immunologically naïve human pop-
ulation has maintained the pandemic potential of these
viruses [6,7].
The cornerstone of most pandemic preparedness plans is
the stockpiling of antiviral drugs against the influenza
virus. Two types of antiviral drugs are available for use
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against influenza, the M2 inhibitors and the neuramini-
dase inhibitors. However, the emergence of drug resistant
influenza strains raises concern over their effectiveness.
H5N1 viruses resistant to M2 inhibitors are widespread
[8], and the development of resistance to the neuramini-
dase inhibitor, oseltamivir is emerging [9,10]. H5N1
strains exhibiting resistance to oseltamivir were initially
thought to be less fit. However, recent studies have found
that resistant viruses retain their replication efficiency and
pathogenicity [11]. In addition, the effectiveness of the
neuraminidase inhibitors appears to be very time depend-
ant, where treatment started later than 24 hours post
infection is much less effective [12]. Given this environ-
ment, mathematical modeling has predicted that should a
pandemic H5N1 virus emerge with transmission charac-
teristics similar to previous pandemic strains, contain-
ment strategies based solely on the use of antiviral drug
therapy would be ineffective [13].
Recently, we and others have reported the therapeutic effi-
cacy of passive immunization in a HPAI H5N1 mouse
model with either humanized mouse mAb [14], equine
F(ab')2 [15], or human mAb [16], directed against hemag-
glutinin (HA) of H5N1 influenza, highlighting its poten-
tial as a viable treatment option in human cases of H5N1.
Indeed, survival of a person infected with HPAI H5N1 has
been reported after treatment with convalescence plasma
[17]. Influenza viruses rapidly mutate, particularly in the
regions of HA responsible for antigenicity, and this has led
to the emergence of multiple antigenically distinct strains
of H5N1 [18], indicating that escape from the protective
effects of neutralizing antibodies directed against the
known antigenic regions may be rapid. For passive immu-
nization to be useful as a defense against influenza pan-
demic, it will need to overcome such antigenic drifts.
We hypothesize that the development of therapeutic anti-
bodies against epitopes that lie outside of the antigenic
sites may provide some resistance against virus escape,
and be more beneficial for use in passive immunotherapy.
The ability to display antibody fragments on bacteri-
ophage for selection allows strategies to be employed for
isolation of specific antibodies not possible by the con-
ventional animal immunization technologies [19]. This
paper describes isolation of a number of Fab from a naïve
human library, by sequential panning against HA from
antigenically distinct H5N1 strains. The binding of the
recombinant human antibodies to HA was shown to be
independent of the common antigenic regions and several
of the antibodies exhibited neutralization in a cell based
neutralization assay using H5N1-VLP, highlighting their
potential for use in passive immunization against H5N1
virus infection.
Results
Expression of Hemagglutinin
Focusing on mutations within the 140s and 150s anti-
genic loops, alignment of all the HA sequences from
H5N1 viruses isolated throughout 2005 and 2006 depos-
ited into the Influenza Virus Resource maintained by
NCBI [20], revealed eight main groups. A representative of
each of these groups was selected to be cloned for use in
antibody screening and antibody binding analysis (Table
1).
Full-length HAs were constructed by replacing the trans-
membrane domain present in the HA2 subunit with the
trimerization domain 'foldon' of bacteriophage T4 fibritin
(FO), allowing secretion of functionally folded HA trim-
ers [21]. The HA2 subunit of A/Vietnam/1203/04 HA was
mutated to contain the FO sequence and ligated to the
individual HA1 described in table 1 and recombinant bac-
uloviruses were produced by infection of Sf9 cells with the
Table 1: Position of mutation in HA1 compared to A/Vietnam/1203/04
Virus Amino acid position in HA1
140s LOOP 150s LOOP
136 137 138 139 140 141 154 155 156
A/Vietnam/1203/04 (VN04) P Y Q G K S N S T
A/Qing Hai/05 (QH) ....R .. NA
A/WS/Mongolia/2/06 (MON) ....R .. DA
A/DK/Vietnam/376/05 (VN05) .... NP ...
A/CK/Ivory Coast/1787/06 (IC) . H ..R . DNA
A/Zhe Jiang/16/06 (ZHE) ....TP. N .
A/Indonesia/CDC597/06 (IN597) ..L . R .. N .
A/DK/Guangzhou/20/05 (GUAN) ..L ..P . NA
A/Indonesia/5/05 (INDO05) ..L . SP...
A/CK/Indonesia/R60/05 (CKINDO) S . L . DP ..A
a residues similar to A/Vietnam/1203/04 are marked by a periodVirology Journal 2008, 5:130 http://www.virologyj.com/content/5/1/130
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respective pENTR-HA-FO. The cell medium was collected
60 hours after infection of Sf9 cells with the recombinant
baculovirus and allowed to incubate with hexa-histidine
affinity beads (Talon) for two hours at room temperature.
Bound proteins were eluted with 150 mM Imidazole, sub-
jected to trypsin digestion to check for correct folding and
resolved on 12%SDS-PAGE (Fig. 1A). The presence of a
~75 kDa protein which was cleaved into an ~40 kDa and
~27 kDa with trypsin suggested the purified protein was
indeed correctly folded HA. This protein was used for
screening against the Fab-library.
For library panning purposes, H5-VLPs were produced by
the transient expression of MMLV retroviral core and H5
HA alone to HEK293. This was to prevent the selection of
antibodies from the Fab library also binding to NA. It has
been shown that HA was incorporated on the surface of
the viral particles even without the presence of endog-
enous NA or M2, and that these could be released with the
addition of exogenous neuraminidase [22]. The produc-
tion and release of VN04 H5-VLP using exogenous NA
was determined by looking for the presence of HA by
immunoblotting using our humanized anti-HA antibody
VN04-2 [14]. Significant levels of released VN04 H5-VLP
purified on a 30% sucrose cushion, could only be detected
with the addition of exogenous NA (Fig. 1B).
Isolation of anti-H5 Fab-phage
Two different approaches of screening the Humanyx Fab
library were devised to bias selection away from the anti-
genic regions. In the first approach, panning was per-
formed completely against recombinant baculovirus
encoded HAs expressed in insect cells. Phage displayed
Fabs were first selected several times on immunotubes
coated with VN04-PS, followed by QH-FO in order to
increase the binding diversity of the Fabs. After the final
pan against QH-FO, the Fab from 380 single colonies
were tested for their ability to bind to VN04-PS by ELISA,
BstN1 digest of the 172 positive clones allowed grouping
of clones with similar patterns. Sequencing confirmed the
identity of 18 unique clones with the ability to bind to all
of the HA-FO described in table 1 in a confirmatory mon-
oclonal ELISA (Table 2).
In the second approach, panning was performed against a
combination of recombinant baculovirus encoded HA
and H5-virus like particles (VLPs). INDO05-FO was
bound onto magnetic Nickel-coated affinity sepharose
through its hexa-histidine tag on the HA2, of which the
library was put through the first two rounds of selection.
The amplified Fab phages were further selected on immu-
notubes coated with QH-VLP, followed by final selection
on VN04-VLP. Placing the initial selection pressure on a
HA-FO protein ensured that the selection of Fabs was not
directed towards epitopes on the VLPs. Analysis of the Fab
from 190 single colonies identified 25 positives by ELISA
against INDO05-FO, all of which were sequenced to
reveal 15 Fab clones with distinct immunoglobulin
sequences that bound to VN04- and QH-VLPs, as well as
INDO05-FO and QH-FO in a confirmatory monoclonal
ELISA (Table 2).
Analysis of HA-FO and H5-VLP Figure 1
Analysis of HA-FO and H5-VLP. (A) The indicated HA 
foldons from recombinant baculovirus were collected and 
allowed to incubate with Talon resin. Following elution, equal 
amounts were treated with trypsin to check for correct fold-
ing, heat denaturation was used as a control for trypsin activ-
ity. Proteins were resolved on 12% SDS-PAGE and stained 
with coomassie. Mw markers (sizes in kDa, left) and the 
bands representing HA0, HA1 and HA2 are indicated. (B) 
H5-VLP were released from HEK293 cells by addition of 
exogenous NA, the VLP pellet after sucrose cushion purifica-
tion was resolved on 12% SDS-PAGE. Immunoblots were 
probed with α-HA (VN04-2).Virology Journal 2008, 5:130 http://www.virologyj.com/content/5/1/130
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All 33 Fabs were subsequently converted into IgGs and
tested for their binding specificities and neutralizing abil-
ities. Purity of the IgGs was verified using SDS-PAGE anal-
ysis (data not shown) and all but one (αHA2) of the IgGs
could be expressed and purified.
Subunit specificity of Fab derived human IgGs
To determine the domain that our IgGs bind to, HA of the
A/Indonesia/CDC597/06 (IN597-FO) strain was sub-
jected to trypsin digestion and resolved into the HA1 and
HA2 subunits by reducing SDS-PAGE, followed by immu-
nobloting with the IgGs. The majority of the antibodies
that were obtained from the VN04-PS/QH-FO screen
appeared to recognize linear epitopes as they could detect
reduced antigen; except for αHA1 which showed no bind-
ing and αHA14 which seemed to bind to both HA1 and
HA2, all of the antibodies bound to HA2 (Fig. 2) In con-
trast, the antibodies obtained from the INDO05-FO/
VN04-VLP/QH-VLP screen appeared to recognize confor-
mational epitopes, as none of the antibodies bound to
reduced HA on the immunoblots (data not shown).
Table 2: Selection of phage displayed Fabs
H5 Target Total Positive Unique Clone
pans clones clones identity
VN04-PS/QH-FO 4/2 172 18 HA1-18
INDO05-FO/VN04-VLP/QH-VLP 2/1/1 25 15 VLP1-15
HA subunit specificity of Fab derived human IgGs Figure 2
HA subunit specificity of Fab derived human IgGs. Purified IN597-FO was resolved on reducing SDS-PAGE and trans-
ferred to Immunoblots probed with anti-HA Fab-IgGs. Goat anti-human (peroxidase conjugated) was used as the secondary 
signal producing antibody. 1-Untreated IN597-FO; 2-Trypsin-cleaved IN597-FO. The humanized protective antibody VN04-2 
was used as a positive control. for presence of proteins on blot.Virology Journal 2008, 5:130 http://www.virologyj.com/content/5/1/130
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Inhibition of H5N1-VLP uptake in MDCK cells by αHA 
antibodies
Recently, retroviral core particle derived virus-like parti-
cles (VLP) harboring the surface proteins of Venezuelan
equine encephalitis virus and H5N1 have shown their
potential as vaccine candidates and also through inclu-
sion of either luciferase or GFP reporter genes, utility as a
substitute for live virus in cell based neutralization assays
[22-24]. When developing the VLP neutralizing assay, to
ensure that uptake of H5N1-VLP into MDCK cells was
similar to the genuine virus infection, we initially used
H5s where the polybasic cleavage site at the end of HA1
had been replaced with a trypsin cleavage site: addition of
these VLPs to MDCK in the absence of trypsin did not
allow visualization of GFP by immunofluoresence micro-
scopy suggesting that the VLP was unable to fuse with the
cells (data not shown). When the same experiment was
repeated using H5 containing the polybasic cleavage site,
GFP could be observed (Fig. 3A). In addition, our previ-
ously described protective antibody VN04-2 could inhibit
uptake of IN597- but not INDO05-VLP (Fig. 3A), the lat-
ter of which does not bind the VN04-2 antibody [23]. The
necessity of HA cleavage for GFP reporter gene integration
and the inhibitory characteristics displayed by VN04-2,
suggests that H5N1-VLP enter MDCK cells in a similar
mechanism to genuine H5N1 virus.
To test the neutralization potential of our antibodies, all
32 antibodies were tested for their neutralizing efficacy
using IN597-VLP containing the GFP reporter gene. Each
antibody was allowed to incubate with IN597-VLP for 60
min prior to addition to MDCK cells and the number of
cells infected with the VLP was determined after 72 hr, 5
of the antibodies (αHA IgGs #4, #11, #12, #17, #18) were
able to neutralize IN597-VLP infection (Fig. 3B).
To confirm this set of data, the concentration of antibod-
ies used in the neutralization assay was lowered from 5
H5N1-VLP neutralization assays with Fab derived human IgGs Figure 3
H5N1-VLP neutralization assays with Fab derived human IgGs. H5N1-VLP were produced in HEK293 cells and the 
media incubated with 5 ug/ml of the indicated IgG for 60 min prior to addition to MDCK cells. (A) Initial validation of the VLP 
neutralization assay was performed using IN597- and INDO05-VLP with and without VN04-2, fusion of the VLP with MDCK 
was visualized by immunofluorescence microscopy. (B) Testing of the isolated IgG was performed against IN597-VLP and 
fusion of the VLP with MDCK was determined by measuring the number of cells producing GFP by flow cytometry with the 
control assay with no IgG taken as 100%. The humanized protective antibody VN04-2 was used as a positive control.
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ug/ml to 2 ug/ml. At the same time, neutralization against
VN04, INDO05 and QH VLPs were also tested as these
H5-VLPs contain complete HA0 sequences that corre-
spond fully to their genuine virus. While the HA2 region
of H5 does show some genetic variability, the N-terminal
portion of the subunit, containing the fusion peptide is
highly conserved. Indeed, for the H5s used here mutation
is only present in the c-terminal third of HA2. With 2 ug/
ml of IgGs (αHA IgGs #4, #11, #12, #17, #18) used in the
assay, above 90% neutralization was still observed with
IN597 and above 80% with VN04-, INDO05- and QH-
VLP (Fig. 4A). To investigate whether the neutralization of
H5N1-VLPs was similar to that observed with a known
protective antibody, the antibodies were titrated and the
effects on inhibition of H5N1-VLP uptake were observed
and compared to that of the neutralizing antibody VN04-
2 [14]. All 5 of the antibodies showed a dose dependant
response which showed similar characteristics to VN04-2
(Fig. 4B).
Discussion
By using a combination of screening strategies which
involved sequential panning against antigenically distinct
HA of H5N1, we were able to isolate from a naïve human
Fab-phage library 33 unique Fab which exhibited binding
to multiple distinct HA representative of the major anti-
genic changes which had occurred throughout 2005 and
2006. In a cell based neutralization assay using H5N1-
VLP, 5 of these antibodies which show specificity for HA2
were found to be neutralizing in a dose dependant man-
ner, similar to our previously described protective human-
ized antibody, VN04-2, which is against the 140s
antigenic loop present in the HA1 subunit [14].
The majority of studies describing neutralizing antibodies
against influenza HA has utilized either H1N1 or H3N2
and has lead to the characterization of the antigenic
regions within HA1 and underlined inhibition of virus-
cell interaction as the main mechanism [25,26]. Determi-
nation of the structure of H5 has highlighted the similar-
ity in the protein fold to HA of other subtypes [21] and
studies using H5 have shown that neutralizing antibodies
bind to similar antigenic regions [14,16,27,28]. Indeed,
neutralizing antibodies have been used to determine the
extent of antigenic variation within H5N1 isolates [18]
and comparison of the amino acid sequence of H5N1 iso-
lates shows extensive mutation within these regions,
affirming their designation as major antigenic regions.
Variations in the HA antigenic regions are created as pas-
sage of virus through the animal/human hosts produces
selective pressure which favours mutation within these
regions. As such areas of the protein outside of these
regions are relatively conserved, increasing the likelihood
that these regions will be unchanged in a future pandemic
strain of H5N1.
In contrast to HA1, HA2 which is primarily responsible
for mediating the fusion of viral and cell membranes is
relatively conserved. While this may suggest that HA2 is
non immunogenic, natural infection with influenza as
well as vaccination does induce antibodies against HA2
[29,30]. Studies of antibodies against HA2 have high-
lighted their high crossreactivity [31]. However, except for
an antibody against a conformational epitope formed by
HA1 and HA2 which inhibits conformational changes
necessary for fusion [32], these antibodies have been
found to be non-neutralizing in vitro [33,34], even though
some of these antibodies are capable of inhibiting cell-cell
and virus-liposome fusion assays [35]. Recently, despite
the lack of neutralization in vitro, passive administration
of antibodies against HA2, particularly those which can
inhibit the fusion activity of HA, have been shown to be
protective in a H3N2 influenza mouse model [36]. The
five antibodies described here may be the first in vitro neu-
tralizing antibodies specific for HA2, raising the exciting
possibility that these antibodies may be protective against
H5N1 influenza infection in vivo. However, it also raises
the question as to why these antibodies have not been
raised before, when antibodies specific for HA2 are usu-
ally non-neutralizing.
One possibility is that the combination of in vitro selec-
tion of Fab-phage and sequential panning against differ-
ent HA variants may have allowed for the identification of
antibodies against epitopes that are not usually open to
antibody selection during the immune response against
HA, be it from natural infection or vaccination. However,
it also possible that the correlation between neutraliza-
tion activity against VLP and virus observed for antibodies
against Venezuelan equine encephalitis virus may not
apply for these antibodies against H5 hemagglutinin. Fur-
ther study of these antibodies is needed to determine their
actual in vivo protective capacity. Examination of the in
vivo efficacy of these antibodies as well as the mechanism
of neutralization will be the focus of further investigation.
Methods
H5 Hemagglutinin HA1
The HA strains were chosen based on the differences to A/
Vietnam/1203/04 (H5N1) in the main antigenic regions
as shown in Table 1 and their cloning has been described
previously [23]. Briefly, the cDNAs encoding the HA1 sub-
units of the selected HAs listed in Table 1 were produced
by a combination of PCR-based methods and the polyba-
sic protease site (RRRKKR) at the end of HA1 was replaced
by the sequence PQIETR, which allows cleavage of HA0 by
trypsin. The fidelity of each clone was confirmed by
sequencing.Virology Journal 2008, 5:130 http://www.virologyj.com/content/5/1/130
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H5N1-VLP neutralization characteristics of αHA Fab IgG Figure 4
H5N1-VLP neutralization characteristics of αHA Fab IgG. (A) To confirm the neutralization observed with the indi-
cated α-HA Fab IgG, neutralization assays were repeated. IN597 and VN04 were produced with the HA2 of VN04 while QH 
and INDO05 were produced with their respective HA2 in HEK293 cells and the media incubated with 2 ug/ml of the indicated 
IgG for 60 min prior to addition to MDCK cells. Fusion of the VLP with MDCK was determined by measuring the number of 
cells producing GFP by flow cytometry with the control assay with no IgG taken as 100%. (B) Dose dependant neutralization 
was assessed against IN597 H5N1-VLPs, with 8 ug/ml and serial dilutions of the indicated antibodies, as described above. The 
humanized protective antibody VN04-2 was used as a positive control.
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Baculovirus expression
In order to produce soluble HA proteins, we used the
recombinant baculovirus expression method for determi-
nation of the H5 HA structure [21]. Briefly, the transmem-
brane domain present in HA2 subunit of VN04 HA had
been replaced by the 'foldon' (FO) trimerization
sequence, followed by a hexa His-tag at the extreme C-ter-
minus of the construct to enable protein purification.
Full-length HA-FOs were cloned into the pENTR vector by
combining the selected HA1 together with the VN04 HA2-
FO and recombinant baculovirus were produced using the
BaculoDirectTM Baculovirus expression system (Invitro-
gen). For protein expression, the recombinant baculovi-
ruses were used to infect attached Sf9 cells. Sixty hours
after infection, recombinant HA proteins secreted into the
cell culture media were purified using talon affinity resin
(Clontech). Purified HA of A/Vietnam/1203/04 produced
in baculovirus (VN04-PS) was purchased from Protein
Sciences Corp.
H5N1 Virus-like Particles (VLPs)
H5N1-VLPs were produced using non-replicating viral
core particles of the Moloney Murine Leukaemia Virus
(MMLV) and the surface proteins of H5N1 as described
previously [23]. Plasmids encoding the non-replicating
MMLV core particle and GFP reporter gene, pVPack-GP
and pFB-hrGFP respectively were purchased from Strata-
gene. For expression of H5 HA, the HA1 cDNAs (listed in
table 1), together with HA2 were cloned into the CMV
promoter driven expression vector, pXJ. For VN04, QH
and INDO05, their respective HA2 was used; for IN597,
the HA2 of VN04 was used. Following construction of the
full length HA, the polybasic cleavage site at the end of
HA1 was restored and all constructs were confirmed by
sequencing. For expression of N1, the N1 neuraminidase
(NA) of A/Vietnam/1203/04 was synthesized (Gene-
Script) and then cloned into pCI vector (Promega).
To produce H5-VLP for library panning, plasmids encod-
ing the core particle and H5 were transiently transfected
into HEK293 according to the protocol provided with the
MBS Mammalian Transfection Kit (Stratagene). Thirty-six
hours after transfection purified Vibrio Cholera neurami-
nidase (Roche) was added at 2 U/ml, VLPs were collected
forty-eight hours post-transfection by ultracentrifugation
through a 20% sucrose gradient at 22,000 rpm at 4°C for
2 hours.
To produce VLP for neutralization assays, plasmids encod-
ing the core particle, H5, VN04-N1 and the GFP reporter
were transfected as above, forty-eight hours following
transfection, the culture medium was collected to be used
in the assay.
Phage display Fab library screening
Library screening was performed using the naïve human
Fab phage display library HX01 (Humanyx Pte Ltd, Singa-
pore). Antigen targets (HA or H5-VLP) were coated onto
Nunc brand Maxisorb Immunotube or affinity magnetic
beads (where indicated) at 4°C overnight. The coated
tubes/beads and the phage library were separately blocked
in 2% skim milk (Sigma) in PBS for 1 h at room tempera-
ture (RT). Pre-blocked phage mixtures were then incu-
bated with the coated tube/beads for 2 h at RT, unbound
phages were eliminated by washing 3 times with 2% skim
milk in PBS-T(0.05% Tween 20), 3 times with PBS-T and
twice with PBS. For subsequent pans, the washings were
increased to 7 times with 2% skim milk in PBS-T, 7 times
with PBS-T and twice with PBS. Bound phages were eluted
either with 0.5 M triethylamine (TEA) for 10 min at RT or
2 mg/ml trypsin solution for 30 min at 37°C. Eluted
phages were used to infect Escherichia coli TG1 cells
grown to OD600 0.5 and subsequently rescued with M13-
K07 helper phage. The rescued phages were amplified and
plated on 2xTY-agar plates containing 100 ug/ml ampicil-
lin and 25 ug/ml kanamycin and incubated at 30°C over-
night. Plates containing bacteria were scraped into TBS
and purified by PEG precipitation, the same procedure
was repeated for subsequent pans, usually up to 6 pans
were performed. To select for individual antigen-binding
Fab clones, phage-infected TG1 cultures were titrated on
2xTY-agar plates containing 100 ug/ml ampicillin and 2%
glucose. Single colonies were picked the next day into 96-
well plates for expression of Fabs and tested for antigen
recognition properties.
Selection of monoclonal Fab
For expression of Fabs, cultures at ~OD600 0.5 were
induced with 1 mM IPTG and incubated with shaking at
30°C overnight in 96-well plates. Screening of HA-bind-
ing Fabs was performed according to standard ELISA
method. Maxisorb 96-well plates (Nunc) were coated
with 2 ug/ml HA-FO per well at 4°C overnight and
blocked with 4% skim milk in PBS at RT for 1–2 h. Cul-
ture supernatants, diluted 1:1 in blocking buffer, were
added to the coated plates and allowed to incubate for 90
min at RT. Antigen recognitions were detected by peroxi-
dase-conjugated anti-cMyc secondary antibody, followed
by the addition of 3.3', 5.5'-tetramethylbenzidine sub-
strate (Pierce). Clones producing absorbance values 2-
fold higher than background levels were considered to be
positive.
To assess the uniqueness of positive clones, BstN1 restric-
tion digest was performed following PCR amplification of
the Fab coding region and resolved on 3% Agarose gel.
Clones showing similar patterns were grouped and the
identity of the clones was determined by sequencing using
specific primers annealing to the regions of the vectorVirology Journal 2008, 5:130 http://www.virologyj.com/content/5/1/130
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flanking the variable heavy and variable light chains of the
antibody fragment, following plasmid extraction using
Miniprep kits (QIAGEN).
Conversion of Fab-phage to human IgG1
Distinct immunoglobulin sequences were converted to
IgG1 by cloning the Fab our Fab-IgG1 vector through Apa
L1 and Bsm BI. The Fab-IgG1 vector was adapted from the
vector used to produce chimeric VN04-2 previously [14].
Changes to the cloning sites were performed to promote
ease of transferring the variable domains from the Fabs
directly to the IgG1 vector, without affecting the constant
domains within the vector. Constructs encoding the Fab-
IgGs were transfected into human embryonic kidney
(HEK293) cells by use of lipofectamine 2000 (Invitro-
gen). Culture media was collected 72 h post transfection
and fresh media was added to the cells and allowed to
incubate for a further 72 h before collection. Secreted anti-
bodies were purified using recombinant Protein A sepha-
rose (Pierce). Purity of the Fab-IgGs was verified using
SDS-PAGE analysis.
H5N1-VLP neutralization assay
All the HA0 constructs used to produce H5N1-VLP that
were used for neutralization assays contained the polyba-
sic protease site between HA1 and HA2. H5N1-VLP con-
taining the surface proteins H5 HA, VN04 NA and GFP
reporter gene were produced by transient transfection as
described above. At 48 h post-transfection, the viral super-
natant were collected and filtered through a 0.45 micron
filter. The filtered supernatant was then diluted 1:3 in
growth medium and incubated with the test antibody at
RT for 1 h. DEAE-dextran solution was added to the VLP-
antibody mix to a final concentration of 10 ug/ml, before
transferring the solution to Madin-Darby Canine Kidney
(MDCK) cells and incubated at 37°C with 5% CO2. The
cell media was replaced with fresh growth medium after 3
h. Transduction titre was deduced 72 h later from the
number of GFP-positive cells measured by flow cytometry
(FACSCalibur; Beckman Coulter). For experiments using
more than one H5N1-VLP, HA units of each H5N1 was
determined using the standard hemagglutination assay
with 0.5% chicken red blood cells and the input of each
H5N1-VLP standardized.
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